← Leaderboards
Christopher C. Coss
Ohio State University
$949,119
Attributed
$3,796,476
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,796,476 · 2
By mechanism
R01$3,796,476 · 2
Top collaborators
- Thomas A Mace4 shared
- Dwight H. Owen4 shared
- Mitch A Phelps4 shared
- John C Byrd1 shared
- Erin K Hertlein1 shared
- Alice Scott Mims1 shared
Most similar at Ohio State University
Same institution · by research overlap
- Rosa Lapalombella$5,349,017
- Alice Scott Mims$1,588,136
- Deepa Sampath$2,215,864
- Jennifer A. Woyach$6,733,332
- Dwight H. Owen$1,210,636
Others in their field
Other Rising Stars on “Publishing”
- Maximilian Haeussler · University Of California Santa Cruz$12,592,563
- Songthip T. Ounpraseuth · Univ Of Arkansas For Med Scis$10,363,762
- James Cappo · National Jewish Health$9,298,220
- Rick L. Stevens · University Of Chicago$7,200,000
- Hong-Ngoc B. Nguyen · University Of Minnesota$6,812,121
- Katherine Rivera-Spoljaric · Washington University$4,587,360
Research focus
PublishingBiological MarkersNeoplastic CellTherapeutic TargetMacrophageCessation Of LifeImmunosuppressionMediatingResponseTumorCellsMalignant NeoplasmsClinical TrialsAlbuminsCheckpoint TherapyAntitumor ResponseAnti-Tumor Immune ResponseAffectClinical PharmacologyCancer CellCancer CachexiaAnti-Pd1 TherapyCancer EtiologyCachexia
Grant awards (5)
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$1,263,739
R01 · FY2025 · CA
Pharmacodynamically directed targeted therapy for leukemia$683,472
R01 · FY2025 · CA
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$594,010
R01 · FY2024 · CA
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$615,393
R01 · FY2023 · CA
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$639,862
R01 · FY2022 · CA